

DAFTAR PUSTAKA

1. Ma J, Cao S. The epidemiology of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AW, editors. Nasopharyngeal cancer multidisciplinary management. 1st ed. New York: Springer; 2010. p. 1-7.
2. Petersson F. Nasopharyngeal carcinoma: A review. *Semin Diagn Pathol*. 2015;32(1):54-73.
3. Kimura Y, Suzuki D, Tokunaga T, Takabayashi T, Yamada T, Wakisaka N, et al. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005. *Auris Nasus Larynx*. 2011;38(2):244-9.
4. Poh SS, Chua MLK, Wee JTS. Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. *Chin J Cancer*. 2016;35:1-9.
5. Ferrari D, Codecà C, Bertuzzi C, Broggio F, Crepaldi F, Luciani A, et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a western population. *BMC Cancer*. 2012;12:1-7.
6. Chen M, Yin L, Wu J, Gu JJ, Jiang XS, Wang DJ, et al. Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma. *Biomed Research International*. 2015:1-5.
7. Mahdavifar N, Ghoncheh M, Hafshejani AM, Khosravi B, Salehiniya H, et al. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia. *Osong Public Heal Res Perspect*. 2016;7(6):360-72.
8. Woo JKS, Hasselt CAV. Nasopharyngeal carcinoma. In: Gleeson M, Browning GG, Burton MJ, Clarke R, Hibbert J, Jones NS, et al, editors. *Scott-Brown's Otorhinolaryngology, Head and Neck Surgery*. 7th ed. London: Edward Arnold; 2008. p. 2445-70.
9. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chin J Cancer*. 2012;31(4):185-96.
10. Salehiniya H, Mohammadian M, Hafshejani AM, Mahdavifar N. Nasopharyngeal cancer in the world: epidemiology, mortality and risk factors. *World Cancer Research Journal*. 2018;5(1):1-8.
11. Yenita, Asri A. Korelasi antara *latent membrane protein-1* virus Epstein-Barr dengan P53 pada karsinoma nasofaring. *Jurnal Kesehatan Andalas*. 2012; 1(1): 1-5.
12. Rahman S, Subroto H, Novianti D. Clinical presentation of nasopharyngeal carcinoma in West Sumatra, Indonesia. *Proceeding of the 20th World Congress of IFOS, 2013*. Seoul, Korea.
13. Chan JKC, Slootweg PJ, Petersson BF, Bell D, Fi-Mofty SK, Gillison M, et al. Tumours of nasopharynx. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. *WHO classification of head and neck tumours*. Lyon: International Agency for Research on Cancer; 2017. p. 63-76.
14. Handayani R, Lisnawati, Tanurahardja B. Ekspresi imunoglobulin A pada sel plasma di sekitar sel tumor karsinoma nasofaring tidak berkeratin, tidak berdiferensiasi yang terinfeksi virus Epstein-Barr. *Majalah Patologi*. 2013;22(3):30-5.

15. Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling pathway : an update on molecular biomarkers. *International Journal of Cell Biology*. 2012;1-10.
16. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprise. *Nat Publ Gr*. 2016;1-14.
17. Breda E, Catarino RJ, Azevedo I, Lobao M, Monteiro E, Medeiros R. Epstein-Barr virus detection in nasopharyngeal carcinoma-implications in a low-risk area. *Braz J Otorhinolaryngol*. 2010;76(3):310-5.
18. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. *Phil. Trans. R. Soc. B*. 2017:1-15.
19. Su WH, Hildesheim A, Chang YS. Human leukocyte antigens and Epstein-Barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers. *Cancer Epidemiology and Prevention*. 2013;3:1-9.
20. Yu KJ, Gao X, Chen CJ, Yang XR, Diehl SR, Goldstein A, et al. Association of human leukocyte antigens with nasopharyngeal carcinoma in high-risk multiplex families in Taiwan. *Hum Immunol*. 2009;70(11):910-4.
21. Hassen E, Nahla G, Bouaaouina N, Chouchane L. The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk. *Mol Biol Rep*. 2010;37(1):119-26.
22. Yurnadi, Soeharso P, Suryandari DA, Moeloek N, Susworo R. Genotype distribution of T cell receptor β gene in Indonesian nasopharyngeal carcinoma patients. *Med J Indones*. 2011;20:171-7.
23. Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, et al. Evaluation and integration of genetic signature for prediction risk of nasopharyngeal carcinoma in southern China. *Int J Cancer*. 2015;124(12): 2942-7.
24. Goldsmith DB, West TM, Morton R. HLA associations with nasopharyngeal carcinoma in southern chinese : a meta-analysis. *Clin Otolaryngol Allied Sci*. 2002;27(1): 61-7.
25. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. *Journal of the National Cancer Institute*. 2002;94(23):1780-9.
26. Hsu WL, Tse KP, Liang S, Chien YC, Su WH, Yu KJ, et al. Evaluation of human leukocyte antigen-A (HLA-A), other non-HLA markers on chromosome 6p21 and risk of nasopharyngeal carcinoma. *PloS One*. 2012;7(8):4-9.
27. Judajana R. Asosiasi human leucocyte antigen (HLA) dan karsinoma nasofaring (KNF). *Indones J Clin Pathol Med Lab*. 2009;15(2)52-6.
28. Djufri NI. Peran Ekspresi HLA-A*02, polimorfisme gen CYP2E1 dan nitrosamin terhadap stadium karsinoma nasofaring (disertasi). Makassar: Universitas Hasanuddin; 2015.
29. Tan L, Loh T. Benign and malignant tumors of the nasopharynx. In: Flint PW, Haughey BH, Lund VJ, Niparko JK, Richardson MA, Robbins KT, editors. *Cummings otolaryngology head & neck surgery*. Fifth edition. Philadelphia: Elsevier; 2010. p. 1348-57.
30. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. *Lancet*. 2016;387:1012-24.

31. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez T, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. *J Immunother*. 2010;33(9):983-90.
32. Wei WI, Chua DT. Nasopharyngeal carcinoma. In: Johnson JT, Rosen CA, Newlands, Amin M, Branstetters B, Casselbrant M, et al, editor. *Bailey's head and neck surgery otolaryngology*. Fifth edition. Philadelphia: Lippincot William & Wilkin; 2014. p. 1875-97.
33. Li X, Fasano R, Ena W, Yao KT, Marincola FM. HLA associations with nasopharyngeal carcinoma. *Curr Mol Med*. 2009;9(6):751-65.
34. Low JSY, Chin YM, Mushiroda T, Kubo M, Govindasamy GK, Pua KC, et al. Genome wide study of copy number variation associated with nasopharyngeal carcinoma in Malaysian chinese identifies CNVs at 11q14.3 and 6p21.3 as candidate loci. *Plos One*. 2016:1-17.
35. Yuliwulandari R, Tokunaga K. Nasopharyngeal carcinoma (NPC) related human leucocyte antigen (HLA) haplotype sharing among Southern East Asian population. *Global Medical and Health Communication*. 2017;5(1):1-12.
36. Stafford ND. Tumours of the nasopharynx. In: Hussain SM, editor. *Logan Turner's disease of the nose, throat and ear*. 11th ed. Florida: Taylor & Francis Group; 2016. p. 209-13.
37. Ondrey FG, Wright SK. Neoplasm of nasopharynx. In: Snow JB, Ballenger JJ, editors. *Ballenger's otorhinolaryngology head and neck surgery*. 16th ed. Ontario: BC Decker Inc; 2003. p. 1392-1407.
38. Liu Y, Du C, Lin C, Chan C, Wang J. Increase morbidity from nasopharyngeal carcinoma and chronic pharyngitis or sinusitis among workers at a newspaper printing company. *Epidemiol Rev*. 2002;59:18-22.
39. Gonzales D, Robbins KT. Carcinoma of the oral cavity, pharynx, and esophagus. In: Chan Y, Goddard JC, editors. *K.J. Lee's essential otolaryngology head and neck surgery*. 11th ed. New York: McGraw-Hill Education; 2016. p. 701-26.
40. Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011. Rosette stone for NPC: genetics, viral infection, and other enviromental factors. *Seminars in Cancer Biology*. 2012;22:107-16.
41. Xie SH, Yu ITS, Tse LA, Au JSK, Lau JSM. Occupational risk factors for nasopharyngeal carcinoma in Hong Kong Chinese: a case-referent study. *Int Arch Occup Environ Health*. 2017:1-7.
42. Naini AS, Raad N, Ghorbani J, Chaibakhsh S, Daryasar RR. Incidence trends and geographical distribution of nasopharyngeal carcinoma in Iran. *Iranian Journal of Cancer Prevention*. 2009:24-8.
43. Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. *Chin J Cancer*. 2014;33(12):1-14.
44. Tang F, Tang X, Tian D, Cao Y. Chemical carcinogenesis and nasopharyngeal carcinoma. In: Chen SS, editor. *Carcinogenesis, diagnosis, and molecular targeted treatment for nasopharyngeal carcinoma*. Rijeka: InTech; 2012. p. 61-82.
45. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. early detection

- of nasopharyngeal carcinoma. *International Journal of Otolaryngology*. 2011;1-6.
46. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2006;15(10):1765-77.
 47. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: Occupational exposures particles, formaldehyde and heat. *Int J Epidemiol*. 2000;29(6):991-8.
 48. Bosetti C, McLaughlin JK, Tarone RE, Pira E, La Vecchia C. Formaldehyde and cancer risk: A quantitative review of cohort studies through 2006. *Ann Oncol*. 2008;19(1):29-43.
 49. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality from solid cancers among workers in formaldehyde industries. *Am J Epidemiol*. 2004;159(12):1117-30.
 50. Ekburanawat W, Ekpanyaskul C, Brennan P, Kanka C, Tepsuwan K, Temiyastith S, et al. Evaluation of non-viral risk factors for nasopharyngeal carcinoma in Thailand: Results from a case-control study. *Asian Pacific J Cancer Prev*. 2010;11:929-32.
 51. Guo X, Johnson R, Deng H, Liao J, Nelson G, Tang M, et al. Evaluation of non viral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. *Int J Cancer*. 2015;142(5):669-71.
 52. Zheng Y, Parsonage G, Zhuang X, Machado LR, James CH, Salman Asmaa, et al. Human leucocyte antigen (HLA) A*1101-restricted Epstein-Barr-specific T-cell receptor gene transfer to target nasopharyngeal carcinoma. *American Association for Cancer Research*. 2015:1-32.
 53. Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM. Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. *Therapeutic and Clinical Risk Management*. 2014;10:721-36.
 54. Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. *Virologica Sinica*. 2015;30(2):107-21.
 55. Tang M, Lautenberger JA, Gao X, Sezgin E, Hendrickson SL, Troyer JL, et al. The Principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. *PLoS Genet*. 2012;8(11):1-11.
 56. Mak HW, Lee SH, Chee J, Tham I, Goh BC, Chao SS, et al. Clinical outcome among nasopharyngeal cancer patients in a multi-ethnic society in Singapore. *Plos One*. 2015:1-13.
 57. Lee AWM, Lydiatt WM, Colevas D, Glastonbury CM, Le QTX, O'Sullivan B, et al. *Nasopharynx AJCC. cancer staging manual*. 8th ed. Chicago: Springer; 2017.
 58. Wei WI, Kwong DLW. Current management strategy of nasopharyngeal carcinoma. *Clin Exp Otorhinolaryngol*. 2010;3(1):1-12.
 59. Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. *Head Neck*. 2014;36(4):511-6.
 60. Afridi S, Hoessli DC, Hameed MW. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. *Immunol Rev*. 2016;272(1): 151-68.

61. Mosaad YM. Clinical role of human leukocyte antigen in health and disease. *Scandinavian Journal of Immunology*. 2015;82:283-306.
62. Abbas AK, Lichtman AH. Antigen capture and presentation to lymphocytes. In: *Basic immunology function and disorders of the immune system*. 3rd ed. Philadelphia: Saunders Elsevier; 2009. p. 45-65.
63. Ayna TK, Kocygit AO. Detection of anti-HLA antibodies by Flow cytometry. In: Schmid I, editor. *Flow Cytometry Select Topics*. InTech; 2016. p. 131-53.
64. Murphy NM, Burton M, Powell DR, Rossello FJ, Cooper D, Chopra A, et al. Haplotyping the human leukocyte antigen system from single chromosomes. *Nat Publ Gr*. 2016:1-9.
65. Caron E, Kowalewski DJ, Koh CC, Sturm T, Schuster H, Aebersold R. Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry. *Molecular & Cellular Proteomics*. 2015:3105-17.
66. Berlingerio M, Bonchi F, Curcio M, Giannotti F. Mining clinical, immunological, and genetic data of solid organ transplantation. In: Sidhu AS, Dillon TS, editors. *Biomedical data and application*. Berlin: Springer-Verlag; 2009. p. 211-36.
67. Werner JM, Freund C. Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation. *Frontiers in Immunology*. 2017;8:1-16.
68. Fisette O, Wingbermühle S, Tampé R, Schäfer LV. Molecular mechanism of peptide editing in the tapasin-MHC I complex. *Sci Rep*. 2016;6:1-13.
69. Kobayashi KS, Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. *Immunology*. 2012;12:813-9.
70. Taylor GS, Steven NM. Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. *Chin Clin Oncol*. 2016;5(5):1-14.
71. Wang RZ, Zhang DG, Wu R, Hu YH, Peng YC, Chang C, et al. HLA-A*02-B*46 haplotype: an adverse prognostic factor in Han patients with nasopharyngeal carcinoma. *J Huazhong Univ Sci Technol*. 2016;36(5):700-4.
72. Dardari R, Hyatti M, Jouhadi H, Benider A, Ettayebi H, Kahlain A, et al. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. *Int J Cancer*. 2001;92:294-7.
73. Li X, Ghandri N, Piancatelli D, Adams S, Chen D, Robbins FM, et al. Associations between HLA Class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. *Journal of Translational Medicine*. 2007;5(22):1-13.
74. Baizig NM, Gorgi Y, Elghourabi M, Makhlouf M, Boussen H, Gritli S, et al. HLA-A*026-A*30 could be predictors of nasopharyngeal carcinoma risk in high-risk Tunisian families. *Journal of Oral Science*. 2017;59(2):289-96.
75. Savitri E, Kuhuwael FG, Punagi AQ, Agus IG. HLA-A*024 gen allele at peripheral blood samples and nasopharyngeal cytobrush in nasopharyngeal carcinoma patients in Makassar. *Int J Biol Med Res*. 2014;5(3):4350-4.
76. Munir D. Gen HLA-DRB1 pada karsinoma nasofaring etnik Batak. *Majalah Kedokteran Nusantara*. 2007;40(3):3-6.
77. Yuliwulandari R, Rochani JT, Indrawati I. Pengelompokan genotip, serologi dan supertipe gene HLA kelas I pada suku Jawa, Indonesia. *Jurnal Kedokteran Yarsi*. 2010;18(2):86-93.
78. Komalawati, Indriaty E, Supartinah A. Profil jaringan lunak dan keras wajah

- lelaki dan wanita dewasa etnis Aceh berdasarkan keturunan campuran Arab, Cina, Eropa dan Hindia. *Cakradonya Dent J.* 2013; 5(2):542-618.
79. Variasi kefalometri pada beberapa etnik di Sumatera Barat. *J. Bio. UA.* 201;2(2): 130-7.
 80. Naim A, Syaputra H. Kewarganegaraan, suku bangsa, agama dan bahasa sehari-hari penduduk Indonesia. Jakarta: Badan Pusat Statistik; 2011. p. 8-10.
 81. Putra RM, Hafiz A, Irfandy D, Bachtiar H. Gambaran analisis klinis wajah mahasiswa/i etnis Minangkabau dengan menggunakan *rhinobase software* (tesis). Padang: Universitas Andalas; 2018.
 82. Sastroasmoro S, Ismael S. Dasar-Dasar Metodologi Penelitian Klinis. Edisi ke-5. Jakarta: Sagung Seto; 2016.
 83. Tang M, Zeng Y, Poisson A, et al. Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. *Genes and Immunity.* 2010:334-42.
 84. Liang B, Zhu L, Liang Z, et al. A Simplified PCR-SSP Method for HLA-A*02 Subtype in a Population of Wuhan, China. *Cellular & Molecular Immunology.* 2006:453-8.
 85. Naomi SM, Dewi YA, Agustina H. Hubungan derajat histopatologi dengan stadium klinis pada karsinoma nasofaring. *Journal of Medicine and Health.* 2018;2(2):730-7.
 86. Xie SH, Yu IT, Tse LA, Au JSK, Lau JSM. Occupational risk factors for nasopharyngeal carcinoma in Hong Kong Chinese: a case-referent study. *Int Arch Occup Environ Health.* 2017:1-7.
 87. Robinson M, Suh Y, Paleri V, Devlin D, ayaz B, Pertl L, et al. Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. *Infectious Agents and Cancer.* 2013;8:1-7.
 88. Diniati A, Ade W, Harianto. Distribusi keganasan nasofaring berdasarkan pemeriksaan histopatologi pada rumah sakit di kota Pekanbaru tahun 2009-2013. *JOM FK.* 2016;3(1):1-18.
 89. Anwar HK, Sukri R, Budiman BJ, Yerizel Eti, Bachtiar H. Perbedaan kadar imunoglobulin-A anti viral capsid antigen dan anti early antigen virus Epstein-Barr pada karsinoma nasofaring di RSUP Dr. M. Djamil Padang (tesis). Padang. Universitas Andalas; 2016.
 90. Maubere F, Nuaba IGA. Karakteristik pasien karsinoma nasofaring di poliklinik telinga hidung tenggorok - kepala leher rumah sakit umum pusat Sanglah Denpasar pada bulan november - desember 2014. *e-journal medika udayana.* 2015;4(2):1-18.
 91. Sarmiento MPCB, Mejia MBA. Preliminary assessment of nasopharyngeal carcinoma incidence in the Philippines: a second look at published data from four centers. *Chin J Cancer.* 2014;33(3):159-64.
 92. Wu L, Li C, Pan L. Nasopharyngeal carcinoma: a review of current updates. *Experimental and Therapeutic Medicine.* 2018;15:3687-92.
 93. Aninditha T, Soebroto AD, Nurhayati E. Komplikasi neurologis pada karsinoma nasofaring. *eJKI.* 2018;6(2):123-7.
 94. Faiza S, Rahman S, Asri A. karakteristik klinis dan patologis karsinoma nasofaring di Bagian THT-KL RSUP Dr. M. Djamil Padang. *J Kesehatan Andalas.* 2016;11:929-32.

95. Melani W, Sofyan F. Karakteristik penderita kanker nasofaring di rumah sakit H. Adam Malik Medan tahun 2011. E-Jurnal FK-USU. 2013;185-96.
96. Munir D. Peran HLA pada karsinoma nasofaring. Maj Kedok Nusant. 2006;39(3):324-30.
97. Rahman S. Hubungan DNA virus Epstein-Barr, alel HLA-DRB1 dan polimorfisme gen CYP2E1 dengan kejadian karsinoma nasofaring pada etnik Minangkabau (disertasi). Padang: Universitas Andalas; 2019.
98. Sari JTY, Rahman S, Hafiz A, Yerizel E, Bachtiar H. Hubungan alel human leucocyte antigen A*11 dengan kejadian karsinoma nasofaring pada etnik Minangkabau di RSUP Dr. M. Djamil Padang (tesis). Padang: Universitas Andalas; 2019.
99. Di D, Sanchez-Mazas A. Challenging views on the peopling history of East Asia: the story according to HLA markers. Am J Phys Anthropol. 2011;45(1):81-96.
100. Wulandari LGI. Analisis faktor risiko kanker nasofaring di rumah sakit umum pusat Sanglah (skripsi). Bali: Universitas Udayana; 2015.

